<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341962</url>
  </required_header>
  <id_info>
    <org_study_id>P2-IMU-838-UC</org_study_id>
    <secondary_id>P2-IMU-838-UC</secondary_id>
    <secondary_id>2017-003703-22</secondary_id>
    <nct_id>NCT03341962</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-finding IMU-838 for Ulcerative Colitis</brief_title>
  <acronym>CALDOSE-1</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunic AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunic AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding
      study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy
      with an option for open-label treatment extension in moderate-to-severe ulcerative colitis
      (CALDOSE-1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational medicinal product (IMP) IMU-838 (vidofludimus calcium) is a new compound
      that selectively inhibits the human enzyme dihydroorotate dehydrogenase (DHODH).
      Dihydroorotate dehydrogenase plays a major role in the de-novo pyrimidine synthesis and is
      specifically expressed at high levels in proliferating or activated lymphocytes. Resting
      lymphocytes satisfy their pyrimidine requirements through a DHODH-independent salvage
      pathway. Thus, IMU-838-mediated DHODH inhibition selectively affects activated, rapidly
      proliferating lymphocytes. The metabolic stress secondary to DHODH inhibition leads to a
      reduction of pro-inflammatory cytokine release including interleukin (IL)-17 (IL-17A and
      IL-17F) and interferon gamma (IFNÎ³), and to an increased apoptosis in activated lymphocytes.

      This is a phase 2, multicenter, randomized, double-blind, and placebo-controlled trial in
      patients with moderate-to-severe UC with an option for open-label treatment extension. The
      study comprises a blinded induction phase to establish the optimal dose of IMU-838 to induce
      response and remission, a blinded maintenance phase to evaluate the potential of IMU-838 to
      maintain remission until Week 50, and an open-label treatment extension arm for all patients
      who discontinue the blinded phase as scheduled or prematurely, subject to certain
      restrictions. A subset of patients will undergo a pharmacokinetic (PK) period at the start of
      the open-label period to establish a full single-dose PK profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic remission and endoscopic healing</measure>
    <time_frame>Week 10</time_frame>
    <description>Composite endpoint: Proportion of patients with both, symptomatic remission and endoscopic healing at Week 10.
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who were randomized to 30 mg/day and 45 mg/day will be used for the assessment of the primary efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic remission and endoscopic healing at different doses</measure>
    <time_frame>Week 10</time_frame>
    <description>Proportion of patients with both symptomatic remission and endoscopic healing at Week 10
(all individual IMU-838 doses will be compared with one another and to placebo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic remission during induction</measure>
    <time_frame>22 weeks</time_frame>
    <description>Proportion of patients achieving symptomatic remission during the induction phase (including extended induction phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieving symptomatic remission</measure>
    <time_frame>22 weeks</time_frame>
    <description>Time to achieving symptomatic remission within the induction/extended induction phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical response</measure>
    <time_frame>10 weeks</time_frame>
    <description>Proportion of patients with clinical response at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with endoscopic healing</measure>
    <time_frame>Week 10</time_frame>
    <description>Proportion of patients with endoscopic healing at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic response</measure>
    <time_frame>22 weeks</time_frame>
    <description>Proportion of patients with symptomatic response during the induction phase (including extended induction phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full Mayo Score</measure>
    <time_frame>Week 10</time_frame>
    <description>Change in full Mayo Score compared to baseline at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo Score</measure>
    <time_frame>Up to Week 22</time_frame>
    <description>Change in partial mayo score over 10 or 22 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO)-2 Mayo Score</measure>
    <time_frame>Up to Week 22</time_frame>
    <description>Change in PRO-2 mayo score over 10 or 22 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin (fCP)</measure>
    <time_frame>Changes from Baseline over 10 or 22 weeks</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Changes from Baseline over 10 or 22 weeks</time_frame>
    <description>Change in the presence of biomarker CRP in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Incidence and Severity of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of participants with clinically significant findings during physical examination</measure>
    <time_frame>up to Week 50</time_frame>
    <description>The emergence of any clinically significant findings compared to screening will be captured during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: body weight</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in body weight during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: blood pressure</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in blood pressure (mm Hg) during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: heart rate</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in heart rate (beats per minute) during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of patients with clinically significant changes in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Hematology</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal hematology laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Blood Chemistry</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal blood chemistry laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Coagulation</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal coagulation laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Urinalysis</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal urinalysis laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Micro ribonucleic acid expression</measure>
    <time_frame>pre-dose and 24 hours post-dose</time_frame>
    <description>Micro ribonucleic acid-122 (miR-122) expression (before first dose and 24 hours after first dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: IMU-838 trough level</measure>
    <time_frame>up to Week 10</time_frame>
    <description>Measurement of pre-dose (trough) blood plasma levels of IMU-838 throughout the induction period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: IMU-838 plasma level</measure>
    <time_frame>Week 2</time_frame>
    <description>Measurement of post-dose blood plasma levels of IMU-838 at Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: area under the drug concentration-time curve (AUC) from time zero to 24 hours (AUC0-24h)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-24h in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC time zero to last measurable concentration (AUC0-t)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-t in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC time zero to infinity (AUC0-inf)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-inf in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: maximum plasma concentration (Cmax)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of Cmax in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: time to Cmax (Tmax)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of Tmax in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with symptomatic response</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Proportion of patients in symptomatic remission by visit up to Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Mayo PRO-2 score</measure>
    <time_frame>Week 50</time_frame>
    <description>Time course of Mayo PRO-2 score until Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Time to relapse</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Time to symptomatic ulcerative colitis (UC) relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients without relapse</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients without symptomatic UC relapse until Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: fCP</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: CRP</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Change in the presence of biomarker CRP in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with endoscopic healing</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients with endoscopic healing at Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with microscopic healing</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients with microscopic healing at Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: corticosteroid-free remission</measure>
    <time_frame>Week 50</time_frame>
    <description>Corticosteroid-free remission at Week 50 in patients receiving corticosteroids at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: symptom control</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Proportion of patients with symptom control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: fCP</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: CRP</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Change in the presence of biomarker fCP in blood samples</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>10 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (during induction)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (during maintenance)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 for up to 10 years and up to 3 years in UK sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMU-838</intervention_name>
    <description>IMU-838 tablet</description>
    <arm_group_label>10 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_label>10 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Open-label)</arm_group_label>
    <arm_group_label>45 mg IMU-838 (Induction)</arm_group_label>
    <other_name>IM90838</other_name>
    <other_name>vidofludimus calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets manufactured to mimic IMU-838 tablets</description>
    <arm_group_label>placebo (during induction)</arm_group_label>
    <arm_group_label>placebo (during maintenance)</arm_group_label>
    <other_name>Placebo (for IMU-838)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Induction phase

          1. Male and female patients, aged 18 - 80 years

          2. UC diagnosed more than 3 months before Screening (Day-30) as documented in the medical
             chart

          3. Previous treatment failure defined as:

               1. Patient had an inadequate response with, lost response to, or was intolerant to
                  approved or experimental immunomodulators (azathioprine, 6-mercaptopurine,
                  6-thioguanine, methotrexate, or tofacitinib) or biologics (no more than 2
                  treatment failures with biologic drugs i.e. anti-tumor necrosis factor Î±
                  antibodies [infliximab, adalimumab, golimumab and their biosimilars],
                  vedolizumab, or certain experimental antibodies [ustekinumab]); or

               2. Patient had an inadequate response to, was intolerant to, or is corticosteroid
                  dependent (corticosteroid-dependent patients are defined as i) unable to reduce
                  steroids below the equivalent of prednisolone 10 mg/day within 3 months of
                  starting steroids, without recurrent active disease, or ii) who have a relapse
                  within 3 months of stopping steroids.)

          4. Active disease defined as

             a. Mayo stool frequency score of â¥2 at Screening Visit 1 b. Mayo rectal bleeding score
             of â¥1 at Screening Visit 1 c. modified Mayo endoscopy subscore of â¥2 at the screening
             flexible sigmoidoscopy (endoscopy assessed by an independent central reader blinded to
             screening center and patient information)

          5. Endoscopic appearance typical for UC and extending &gt;15 cm from the anal verge as
             confirmed by an independent central reader (blinded to screening center and patient
             information)

          6. Laboratory values: Neutrophil count &gt;1500 cells/ÂµL, platelet count â¥100 000 /mm3,
             serum creatinine &lt;1.5 x upper limit of normal (ULN), total bilirubin, alanine
             aminotransferase (ALT), and gamma-glutamyl transferase (GGT) &lt;1.5 x ULN

          7. Female patients must:

             a. Be of non-child-bearing potential i.e. surgically sterilized (hysterectomy,
             bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before Screening) or
             post-menopausal (where postmenopausal is defined as no menses for 12 months without an
             alternative medical cause), or

             b. If of child-bearing potential, must have a negative pregnancy test at Screening
             (blood test) and before the first study drug administration (Day 0 urine test). They
             must agree not to attempt to become pregnant, must not donate ova, and must use a
             highly effective contraceptive method 2 months before Screening, during treatment with
             IMU-838, and at least 3 months after the last dose of study therapy

             Highly effective forms of birth control are those with a failure rate less than 1% per
             year and include:

             - oral, intravaginal, or transdermal combined (estrogen and progestogen containing)
             hormonal contraceptives associated with inhibition of ovulation

               -  oral, injectable, or implantable progestogen-only hormonal contraceptives
                  associated with inhibition of ovulation

               -  intrauterine device or intrauterine hormone-releasing system

               -  bilateral tubal occlusion

               -  vasectomized partner (i.e. the patient's male partner has undergone effective
                  surgical sterilization before the female patient entered the clinical trial and
                  he is the sole sexual partner of the female patient during the clinical trial)

               -  sexual abstinence (acceptable only if it is the patient's usual form of birth
                  control/lifestyle choice) 8. Male patients must agree not to father a child or to
                  donate sperm starting at Screening and throughout the clinical trial and for 3
                  months after the last dose of study medication.

          8. Male patients must also either

             - abstain from sexual intercourse with a female partner (acceptable only if it is the
             patient's usual form of birth control/lifestyle choice), or

             - use adequate barrier contraception during treatment with IMU-383 and for at least 3
             months after the last dose of study medication

             For Poland and the UK the following additional requirement apply:

               -  if male patients have a female partner of childbearing potential, the partner
                  should use a highly effective contraceptive method as outlined in inclusion
                  criterion 7

             And additionally, for Poland only:

               -  if male patients have a pregnant partner, they must use condoms while taking
                  study medication to avoid exposure of the fetus to study medication

          9. Ability to understand and comply with study procedures and restrictions

         10. The patient is legally competent, has been informed of the nature, the scope and the
             relevance of the study, voluntarily agrees to participation and the study's provisions
             and has duly signed the informed consent form

        Maintenance phase

        1. Symptomatic remission achieved at Week 10 or Week 22 of the induction phase

        Open-label treatment extension arm

        1. Patient is in the induction phase, had received at least 6 weeks of blinded study
        treatment and completed the sigmoidoscopy (incl. biopsy) regularly scheduled at Week 10/End
        of Induction, and has neither reached symptomatic remission nor symptomatic response

        OR

        Patient is in the extended induction phase, had completed all Week 10 assessments, and has
        not reached symptomatic remission during or at the end of the extended induction phase, Or
        Patient is in the maintenance phase and discontinues from the maintenance phase due to
        symptomatic UC relapse or other reasons with a flexible sigmoidoscopy performed at
        discontinuation (if the previous sigmoidoscopy had been performed more than 4 weeks before
        discontinuation)

        OR

        Patient has completed the maintenance phase as scheduled (including all Week 50
        assessments)

        EXCLUSION CRITERIA:

        Gastrointestinal exclusion criteria

          1. Diagnosis of Crohn's disease, inflammatory bowel disease type unclassified, ischemic
             colitis, microscopic colitis, radiation colitis or diverticular disease-associated
             colitis

          2. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine

          3. History of colectomy with ileorectal anastomosis or ileal-pouch anal anastomosis or
             imminent need for colectomy (i.e. colectomy is being planned)

          4. Active therapeutically uncontrollable abscess or toxic megacolon

          5. Malabsorption or short bowel syndrome

          6. History of colorectal cancer or colorectal dysplasia (with the exception of dysplasia
             in polyps which have been removed)

             Infectious disease exclusion criteria

          7. Clostridium difficile (C. difficile) infection

               -  Evidence of, or treatment for C. difficile infection within 30 days before first
                  randomization

               -  Positive C. difficile toxin B stool assay during the screening period

          8. Treatment for intestinal pathogens other than C. difficile within 30 days prior to
             first randomization

          9. Other chronic systemic infections

               -  History of chronic systemic infections including but not limited to tuberculosis,
                  human immunodeficiency virus (HIV), hepatitis B or C, within 6 months before
                  Screening

               -  Positive interferon-gamma release assay (IGRAs) for Mycobacterium tuberculosis at
                  Screening

               -  Positive HBsAg (hepatitis B virus surface antigen), HBcAb (hepatitis B core
                  antibody), positive hepatitis C virus and/or HIV-antigen-antibody (HIV-Ag/Ab)
                  test at Screening

         10. Any live vaccinations within 30 days prior to study drug administration except for the
             influenza vaccine

             Other medical history and concomitant disease exclusion criteria

         11. Known history of nephrolithiasis or underlying condition with a strong association of
             nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia

         12. Diagnosis or suspected liver function impairment which may cause, as assessed by the
             investigator, a potential for fluctuating liver function tests during this trial

         13. Renal impairment i.e. estimated glomerular filtration rate (eGFR) â¤60 mL/min/1.73mÂ²

         14. Serum uric acid levels at Screening &gt;1.2 x ULN (for women &gt;6.8 mg/dL, for men &gt;8.4
             mg/dL)

         15. History or clinical diagnosis of gout

         16. Known or suspected Gilbert syndrome

         17. Indirect (unconjugated) bilirubin â¥1.2 x ULN at Screening (i.e. â¥ 1.1 mg/dL)

         18. Concurrent malignancy or prior malignancy within the previous 10 years except for the
             following: adequately-treated non-melanoma skin cancer and adequately-treated cervical
             cancer

             Therapy exclusion criteria

         19. Use of any investigational product within 8 weeks or 5 x the respective half-life
             before first randomization, whatever is longer

         20. Use of the following medications within 2 weeks before first randomization:

               1. Tofacitinib

               2. Methotrexate,

               3. Mycophenolate mofetil

               4. Any calcineurin inhibitors (e.g. tacrolimus, cyclosporine, or pimecrolimus)

               5. Oral systemic corticosteroids &gt;20 mg/day prednisolone equivalent including
                  beclomethasone dipropionate (at &gt;5 mg/day) and budesonide (multi-matrix [MMX] at
                  &gt;9 mg/day)

               6. Oral aminosalicylates (e.g. mesalazines) &gt;4 g/day

         21. Use of the following medications within 4 weeks before first randomization:

               1. Use of intravenous corticosteroids

               2. Use of thiopurines including azathioprine, mercaptopurine and 6-thioguanine

               3. Use of any rectal and topical aminosalicylates and/or budesonide

         22. Use of oral systemic corticosteroids â¤20 mg/day prednisolone equivalent including
             beclomethasone dipropionate (at â¤5 mg/day) and budesonide (MMX at â¤9 mg/day) unless
             they have been used for at least 4 weeks before first randomization and at a stable
             dose for at least 2 weeks before first randomization

         23. Oral aminosalicylates (e.g. mesalazines) â¤4 g/day unless they have been used for at
             least 6 weeks and with a stable dose for at least 3 weeks before first randomization

         24. Use of biologics as follows:

               1. anti-tumor necrosis factor Î± antibodies (infliximab, adalimumab, golimumab,
                  including their biosimilars) within 4 weeks before first randomization

               2. vedolizumab and ustekinumab within 8 weeks before first randomization

         25. Use of the DHODH inhibitors leflunomide or teriflunomide within 6 months before first
             randomization

         26. Any use of natalizumab (Tysabriâ¢) within 12 months before first randomization

         27. Use of the following concomitant medications is prohibited at Screening and throughout
             the duration of the trial:

               -  any medication known to significantly increase urinary elimination of uric acid,
                  in particular lesinurad (Zurampicâ¢) as well as uricosuric drugs such as
                  probenecid

               -  treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin,
                  bosutinib, sorafenib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib

               -  any drug significantly restricting water diuresis, in particular vasopressin and
                  vasopressin analogs

               -  Rosuvastatin at doses Ë10 mg/day

             General exclusion criteria

         28. History of, or current serious, severe, or unstable (acute or progressive) physical or
             mental illness, or any medical condition, including laboratory anomalies or renal or
             hepatic impairment, that may require treatment or would put the patient in jeopardy if
             he/she was to participate in the study

         29. Known hypersensitivity to DHODH inhibitors (teriflunomide, leflunomide) or any
             ingredient of the investigational product

         30. Pregnancy or breastfeeding

         31. History of drug or alcohol abuse during the past year

         32. Concurrent participation in any other clinical trial using an investigational
             medicinal product or medical device

         33. An employee of an investigator or sponsor or an immediate relative of an investigator

        Exclusion criteria for open-label treatment extension arm

          1. Any ongoing, clinically significant treatment-emergent (started during the IMU-838
             treatment in the blinded treatment arms) adverse event (AE) or laboratory abnormality
             (including blood chemistry and urinalysis) as assessed by the investigator *

          2. Significant treatment or study non-compliance during induction and/or maintenance
             phase (as assessed by the investigator), and/or inability or unwillingness to follow
             instructions by study personnel as assessed by the investigator

          3. Significant protocol deviations during induction and/or maintenance phase that are
             assessed by the investigator to negatively affect further patient cooperation in this
             study

               -  If treatment-emergent AEs are the reason for exclusion from the open-label
                  extension arm, the eligibility can be re-assessed up to 30 days following the
                  last treatment in the blinded treatment arms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Muehler</last_name>
    <role>Study Director</role>
    <affiliation>Immunic Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Muehler</last_name>
    <phone>+49.89.2500 794 64</phone>
    <email>andreas.muehler@immunic.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geert D'Haens</last_name>
    <phone>+31 20 56 63534</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toni Garcia</last_name>
      <phone>520-527-3881</phone>
      <email>tonigarcia@delsolresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gary Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marysol Gonzalez-Villegas</last_name>
      <email>marysol@axistoday.com</email>
    </contact>
    <investigator>
      <last_name>Lydie Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Hazan</last_name>
      <phone>805-200-7436</phone>
      <email>sabinehazan@aim.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Alliance Medical Research, LLC</name>
      <address>
        <city>Lighthouse Point</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilay Mehta</last_name>
      <phone>954-204-0052</phone>
      <email>nilaymrmresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vipin Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medley Research Associates</name>
      <address>
        <city>Medley</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Hernandez</last_name>
      <phone>786-487-4688</phone>
      <email>lhernandez@medleyresearch.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Aviles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Alpizar</last_name>
      <phone>813-873-8102</phone>
      <email>ralpizar@crtfi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sadi Alpizar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Thomas</last_name>
      <phone>404-881-8800</phone>
      <email>fthomas@medicalresearchsolutions.net</email>
    </contact>
    <investigator>
      <last_name>Gary Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, P.C.</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Britschge</last_name>
      <phone>704-647-9913</phone>
      <email>mbritschge@pmg-research.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vlneet Korrapati, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Taliah Sims</last_name>
      <phone>843-789-3707</phone>
      <email>tsims@clinicaltrialssc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Koro Nabeel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Harold Minkowitz</last_name>
      <phone>713-480-3028</phone>
      <email>harold@minkowitzmd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jognesh Shah, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Clark</last_name>
      <phone>281-935-3463</phone>
      <email>laura.clark@covance.com</email>
    </contact>
    <contact_backup>
      <last_name>Julie Coard</last_name>
      <phone>253-503-2514</phone>
      <email>jcoard@washgi.com</email>
    </contact_backup>
    <investigator>
      <last_name>William Holderman, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Durres Regional Hospital</name>
      <address>
        <city>Durres</city>
        <zip>2001</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Indrit Kellici, MD</last_name>
      <phone>(35567)3056252</phone>
      <email>indkel1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Indrit Kellici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Shkoder</name>
      <address>
        <city>Shkoder</city>
        <zip>4001</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luli Nevila, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luli Nevila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Hospital 2</name>
      <address>
        <city>Tirana</city>
        <zip>1000</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Redi Capi, MD</last_name>
      <email>redi.capi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Redi Capi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>1000</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edite Sadiku, MD</last_name>
      <email>edite.sadiku@umed.edu.al</email>
    </contact>
    <investigator>
      <last_name>Edite Sadiku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Trauma</name>
      <address>
        <city>Tirana</city>
        <zip>1000</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Merita Luka</last_name>
      <email>loretaxhiku@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Merita Luka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Trauma</name>
      <address>
        <city>Tirana</city>
        <country>Albania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bardhyl Popa, MD</last_name>
      <phone>(35568)2029665</phone>
      <email>bardhylpopa@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bardhyl Popa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Mikhailova, PhD</last_name>
      <phone>(37529) 646-5206</phone>
      <email>elena.mikhailova@tut.by</email>
    </contact>
    <investigator>
      <last_name>Elena Mikhailova, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Center for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <zip>246040</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vitaliy Krivenchu, MD</last_name>
      <phone>(37523) 237-8092</phone>
      <email>vital755@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vitaliy Krivenchu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vitiebsk State Order of Peoples' Friendship Medical University</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergey Pimanov, PhD</last_name>
      <phone>(37529) 685-7177</phone>
      <email>pimanovs@tut.by</email>
    </contact>
    <investigator>
      <last_name>Sergey Pimanov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Internal Medicine Clinic, Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mladen Djurdjevic, MD</last_name>
      <phone>(3876) 563-8225</phone>
      <email>mladen.djurdjevic@kc-bl.com</email>
    </contact>
    <investigator>
      <last_name>Mladen Djurdjevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Mostar, Internal Medicine Clinic, Department of Gastroenterology</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maja Karin, MD</last_name>
      <phone>(3876) 345-1688</phone>
      <email>majakarin78@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maja Karin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT Yuliya Vrevska Byala EOOD</name>
      <address>
        <city>Byala</city>
        <zip>187100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georgi Lungolov, MD</last_name>
      <phone>(35987) 883-6004</phone>
      <email>g.lungolov@mail.bg</email>
    </contact>
    <investigator>
      <last_name>Georgi Lungolov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Medconsult Pleven&quot; OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kostantin Kostov</last_name>
      <phone>(35988) 204-4271</phone>
      <email>kostovko@abv.bg</email>
    </contact>
    <contact_backup>
      <last_name>Ivanka Marinova, MD., Assoc. Prof.</last_name>
      <phone>(35988) 893-6107</phone>
      <email>marinova_1944@abv.bg</email>
    </contact_backup>
    <investigator>
      <last_name>Ivanka Marinova, MD., Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Exacta Medica</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Lalev, MD</last_name>
      <phone>(35987) 683-4004</phone>
      <email>i.lalev@doctorstudy.eu</email>
    </contact>
    <investigator>
      <last_name>Ivan Lalev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot; EAD, Plovdiv, Gastroenterology clinic</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georgi Yankov</last_name>
      <phone>(35987) 700-6621</phone>
      <email>g.qnkov@unimed.bg</email>
    </contact>
    <contact_backup>
      <last_name>Simon Sariyan, MD</last_name>
      <phone>(35987) 643-9711</phone>
      <email>simonsariyan@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Sariyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Hera&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emil Kostov</last_name>
      <phone>(35988) 843-4996</phone>
      <email>emil.kostov@heraclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Nikolay Tsonev, MD</last_name>
      <phone>(35988) 458-0259</phone>
      <email>office@heraclinics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nikolay Tsonev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diagnostic-Consulting Center &quot;Convex&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elka Vasileva - Ganova</last_name>
      <phone>(35987) 708-1757</phone>
      <email>eli@convex.bg</email>
    </contact>
    <contact_backup>
      <last_name>Ludmila Tankova, MD., Prof.</last_name>
      <phone>(35988) 859-2189</phone>
      <email>drtankova@abv.bg</email>
    </contact_backup>
    <investigator>
      <last_name>Ludmila Tankova, MD., Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Bjelovar</name>
      <address>
        <city>Bjelovar</city>
        <zip>43000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marinko LukiÄ, MD</last_name>
      <phone>(38598) 941-7873</phone>
      <email>marinko.lukicm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marinko LukiÄ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Borzan, MD</last_name>
      <phone>(38591) 521-1171</phone>
      <email>vborzan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Borzan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davor Å timac, MD, PhD, Prof.</last_name>
      <phone>(38591) 501-9332</phone>
      <email>davor.stimac@medri.hr</email>
    </contact>
    <investigator>
      <last_name>Davor Å timac, MD, PhD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Å½eljko Puljitz, MD</last_name>
      <phone>(38598) 983-6020</phone>
      <email>zpuljiz4@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Å½eljko Puljitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Vukovar</name>
      <address>
        <city>Vukovar</city>
        <zip>32000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan PetroÅ¡eviÄ, MD</last_name>
      <phone>(38591) 918-8773</phone>
      <email>petrosevic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ivan PetroÅ¡eviÄ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana BariÅ¡iÄ, MD</last_name>
      <phone>(38591) 155-4745</phone>
      <email>kunovic_ana@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ana BariÅ¡iÄ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Å½eljko Äabrijan, MD, PhD, Prof.</last_name>
      <phone>(38595) 803-1019</phone>
      <email>zcabrijan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Å½eljko Äabrijan, MD, PhD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinic Solmed Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Pavic, MD, PhD, Assist. Prof.</last_name>
      <phone>(3851) 562-0921</phone>
      <email>tajana.pavic@solmed-clinic.com</email>
    </contact>
    <investigator>
      <last_name>Tatjana Pavic, MD, PhD, Assist. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Split</name>
      <address>
        <city>Zagreb</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damir Bonacin, MD, PhD, Assist. Prof.</last_name>
      <phone>(38591) 566-8893</phone>
      <email>damir.bonacin@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Damir Bonacin, MD, PhD, Assist. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o. Poliklinika III</name>
      <address>
        <city>Hradec KrÃ¡lovÃ©</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslava Volfova, Dr.</last_name>
      <phone>(42049) 521-8475</phone>
      <email>miroslava.volfova@hepato-gastro.com</email>
    </contact>
    <investigator>
      <last_name>Miroslava Volfova, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o.</name>
      <address>
        <city>Ostrava - TÅebovice</city>
        <zip>72200</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vit Smajstrla, Dr.</last_name>
      <phone>(42059) 693-8949</phone>
      <email>bormed1@volny.cz</email>
    </contact>
    <investigator>
      <last_name>Vit Smajstrla, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MEDICON a.s. - Poliklinika BudÄjovickÃ¡ Gastroenterologie</name>
      <address>
        <city>Praha</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Klinika ResTrial</name>
      <address>
        <city>Praha</city>
        <zip>14300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Stovicek, Dr.</last_name>
      <phone>(42073) 089-3972</phone>
      <email>jan.stovik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jan Stovicek, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ISCARE I.V.F., a.s. Lighthouse</name>
      <address>
        <city>Praha</city>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>VÅ¡eobecnÃ¡ fakultnÃ­ nemocnice v Praze IV. internÃ­ klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha</city>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ales Novotny, Dr.</last_name>
      <phone>(42022) 496-2506</phone>
      <email>novotnyales@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ales Novotny, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mediendo s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>18600</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lowenberg, MD</last_name>
      <phone>(31020) 566-6545</phone>
      <email>m.lowenberg@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Mark Lowenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid van Liere-Baron</last_name>
      <phone>(31078) 655-1972</phone>
      <email>a.baron@asz.nl</email>
    </contact>
    <investigator>
      <last_name>Frank Wolfhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Sipers</last_name>
      <phone>(31043) 387-5021</phone>
      <email>simone.reneerkens@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jeoffrey Haans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bierens-Peters</last_name>
      <phone>(31013) 221-8466</phone>
      <email>d.peters@etz.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Laheij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City General Hospita 8th September</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jusuf Vejseli, MD</last_name>
      <phone>(38970) 215480</phone>
      <email>jusufvejseli@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jusuf Vejseli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unievrsity Clinic of Gastroenterohepatology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalina Grivcheva Stardelova, MD, PhD, Prof.</last_name>
      <phone>(38970) 335307</phone>
      <email>kalina.stardelova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kalina Grivcheva Stardelova, MD, PhD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Szpital Miejski im. PCK w BiaÅymstoku OddziaÅ ChorÃ³b WewnÄtrznych i Gastroenterologii</name>
      <address>
        <city>BiaÅystok</city>
        <zip>15003</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centrum UsÅug Medycznych MaxMed</name>
      <address>
        <city>Bochnia</city>
        <zip>32700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadeta Gogola-Migdal, MD</last_name>
      <phone>(4869) 593-2321</phone>
      <email>istoklosa@maxmed24.pl</email>
    </contact>
    <investigator>
      <last_name>Bernadeta Gogola-Migdal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Baluta, MD</last_name>
      <phone>(4853) 369-1047</phone>
      <email>krzysztof.flis@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Potrzebowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Endo-med Sp. z o.o.</name>
      <address>
        <city>Karczew</city>
        <zip>05480</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Fijolek, MD</last_name>
      <phone>(4879) 799-4000</phone>
      <email>tf.badania@endo-med.pl</email>
    </contact>
    <investigator>
      <last_name>Tomasz Fijolek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vita Longa Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemyslaw Ramos, MD</last_name>
      <phone>(4878) 464-5050</phone>
      <email>daria.merkuda@researchsolutions.pl</email>
    </contact>
    <investigator>
      <last_name>Przemyslaw Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GLOBE Badania Kliniczne Sp. z o.o.</name>
      <address>
        <city>KÅodzko</city>
        <zip>57300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Dzygora, MD, PhD</last_name>
      <phone>(4853) 572-8015</phone>
      <email>anna.karmazyn@globebadania.pl</email>
    </contact>
    <investigator>
      <last_name>Rafal Dzygora, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie OddziaÅ Gastroenterologii</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halina Cichoz-Lach, MD, PhD</last_name>
      <phone>(4853) 369-1047</phone>
      <email>krzysztof.flis@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Halina Cichoz-Lach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZakÅad leczniczy ALLMEDICA BADANIA KLINICZNE Sp. z o.o. Sp. K.</name>
      <address>
        <city>Nowy Targ</city>
        <zip>34400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikolaj Krzyzanowski, MD</last_name>
      <phone>(4857) 588-6613</phone>
      <email>patrycja.lesnicka@allmedica.pl</email>
    </contact>
    <investigator>
      <last_name>Mikolaj Krzyzanowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Etyka OÅrodek BadaÅ Klinicznych</name>
      <address>
        <city>Olsztyn</city>
        <zip>10117</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Ferenc, MD</last_name>
      <phone>(4860) 965-5234</phone>
      <email>arkadiuszsupczinski@etykaosrodek.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Ferenc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ars Medical - Szpital, Ars Medical - Ambulatorium</name>
      <address>
        <city>PiÅa</city>
        <zip>64920</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Klonowska-Majchrzak, MD</last_name>
      <phone>(4879) 780-8269</phone>
      <email>michal.wisniewski@farmepo.com</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Klonowska-Majchrzak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOLUMED Centrum Medyczne</name>
      <address>
        <city>PoznaÅ</city>
        <zip>60529</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Karczewski, MD, PhD</last_name>
      <phone>(4869) 647-9338</phone>
      <email>natalia.malyska@solumed.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Karczewski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niepubliczny ZakÅad Opieki Zdrowotnej Centrum Medyczne HCP - Lecznictwo Stacjonarne</name>
      <address>
        <city>PoznaÅ</city>
        <zip>61485</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslaw Lenartowicz, MD</last_name>
      <phone>(4860) 411-6632</phone>
      <email>monika.stanley@cmhcp.eu</email>
    </contact>
    <investigator>
      <last_name>Leslaw Lenartowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Horynski, MD, PhD</last_name>
      <phone>(4850) 101-1879</phone>
      <email>badanie.kliniczne@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Horynski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia SzczeciÅskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badawcze WspÃ³Åczesnej Terapii, Prywatny Gabinet Lekarski dr Anna Bochenek-Mularczyk</name>
      <address>
        <city>Warszawa</city>
        <zip>02679</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bochenek, MD</last_name>
      <phone>(4822) 664-7517</phone>
      <email>w.marzewski@cbwt.eu</email>
    </contact>
    <investigator>
      <last_name>Anna Bochenek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Przychodnia Vistamed</name>
      <address>
        <city>Wroclaw</city>
        <zip>53149</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadetta Frysna, MD</last_name>
      <phone>(4851) 481-0834</phone>
      <email>e.krymska@vistamed.pl</email>
    </contact>
    <investigator>
      <last_name>Bernadetta Frysna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne OMNI Clinic Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>WrocÅaw</city>
        <zip>54204</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Wasko-Czopnik, MD, PhD</last_name>
      <phone>(4860) 262-1780</phone>
      <email>dczopnik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dorota Wasko-Czopnik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Med-Gastr Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>ÅÃ³dz</city>
        <zip>91034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Mamos, MD, PhD</last_name>
      <phone>(4850) 235-7277</phone>
      <email>amamos@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Arkadiusz Mamos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salve Medica Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>ÅÃ³dÅº</city>
        <zip>91211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Kotala, MD</last_name>
      <phone>(4850) 760-2151</phone>
      <email>k.majda@salvemedica.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Kotala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e UniversitÃ¡rio de Coimbra, EPE - Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fransisco Portela, MD</last_name>
      <phone>(35123) 940-0541</phone>
      <email>fasportela@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fransisco Portela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital da Senhora da Oliveira - GuimarÃ£es, EPE</name>
      <address>
        <city>GuimarÃ£es</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiago Curdia GonÃ§alves, MD</last_name>
      <phone>(35125) 354-0330</phone>
      <email>tiagomcg@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tiago Curdia GonÃ§alves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Entre o Douro e Vouga, EPE - Hospital SÃ£o SebastiÃ£o</name>
      <address>
        <city>Santa Maria da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rute Cerqueira, MD</last_name>
      <phone>(35125) 637-9700</phone>
      <email>rute.cerqueira@chedv.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Rute Cerqueira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. MEDLIFE S.A., Sectia Gastroenterologie</name>
      <address>
        <city>Bucharest</city>
        <zip>10719</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugeniu Craciun, MD</last_name>
      <phone>(4072) 352-7258</phone>
      <email>eugencraciun@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eugeniu Craciun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina, Sectia Gastroenterologie</name>
      <address>
        <city>Bucharest</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Radu Bogdan Mateescu, MD</last_name>
      <phone>(4072) 258-8451</phone>
      <email>bogmateescu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bogdan Mateescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni, Sectia Clinica Gastroenterologie III</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liliana Gheorge, MD</last_name>
      <phone>(4072) 263-5885</phone>
      <email>drlgheorghe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liliana Gheorghe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Cabinet Particular Policlinic Algomed SRL, Specialitatea Gastroenterologie</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Goldis, MD</last_name>
      <phone>(4072) 241-0712</phone>
      <email>goldisadi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Goldis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Khazova, MD, PhD</last_name>
      <email>hazova_elena@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Elena Khazova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEI HPE &quot;Kuban State Medical University&quot; of MoH and SD, CBHS Regional Clinical Hospital No.2</name>
      <address>
        <city>Krasnodar</city>
        <zip>350072</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Onopriev, MD, PhD, DrMedSci</last_name>
      <phone>(7918) 352-2366</phone>
      <email>onopr@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vladimir Onopriev, MD, PhD, DrMedSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bagdadi Alikhanov, MD, PhD, DrMedSci, Prof.</last_name>
      <phone>(7916) 778-5172</phone>
      <email>alikhanovba@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Bagdadi Alikhanov, MD, PhD, DrMedSci, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal Medical Biophysical Center n.a. Burnazyan</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institution of Moscow Region named after M. F. Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Belousova, MD, PhD, DrMedSci, Prof.</last_name>
      <phone>(7495) 483-3086</phone>
      <email>eabelous@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;Military Medical Academy n.a. S.M. Kirov&quot; under the Ministry of Defence of Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Gordienko, MD, PhD, DrMedSci</last_name>
      <phone>(7901) 320-4360</phone>
      <email>gord503@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Aleksandr Gordienko, MD, PhD, DrMedSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Saint Martyr Elizaveta</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriy Uspenskiy, MD, PhD, DrMedSci, Prof.</last_name>
      <phone>(7812) 543-1313</phone>
      <email>uspenskiy65@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Yuriy Uspenskiy, MD, PhD, DrMedSci, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University named after I.P. Pavlov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luaza Shalieva</last_name>
      <phone>(7952) 213-6965</phone>
      <email>luazash@list.ru</email>
    </contact>
    <contact_backup>
      <last_name>Vasiliy Trofimov, MD, PhD, DrMedSci, Prof.</last_name>
      <phone>(7921) 913-1328</phone>
      <email>trofvi@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Vasiliy Trofimov, MD, PhD, DrMedSci, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 31</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 5 - Sochi</name>
      <address>
        <city>Sochi</city>
        <zip>354207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Kirillova, MD, PhD</last_name>
      <phone>(7913) 888-0637</phone>
      <email>kirillova.natalya@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Natalia Kirillova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional State Autonomous Healthcare Institution &quot;Tomsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Budankova, MD</last_name>
      <phone>(7382) 263-0028</phone>
      <email>budfed83@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Ekaterina Budankova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic for gastroenterohepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petar Svorcan, MD</last_name>
      <phone>(38164) 810-9042</phone>
      <email>svorcanp@open.telekom.rs</email>
    </contact>
    <investigator>
      <last_name>Petar Svorcan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Predrag Dugalic, MD</last_name>
      <phone>(38164) 854-3101</phone>
      <email>predrag.dugalic@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Predrag Dugalic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Bezaniska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Brankovic, MD</last_name>
      <phone>(38164) 015-0022</phone>
      <email>manive23@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marija Brankovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biljana Milojkovic Kicevska, MD</last_name>
      <phone>(38164) 229-6143</phone>
      <email>draganki1@msn.com</email>
    </contact>
    <investigator>
      <last_name>Biljana Milojkovic Kicevska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Leskovac</name>
      <address>
        <city>Leskovac</city>
        <zip>16000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SaÅ¡a Grgov, MD</last_name>
      <phone>(381064) 210-2733</phone>
      <email>grgovs@gmail.com</email>
    </contact>
    <investigator>
      <last_name>SaÅ¡a Grgov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Nagorni, MD</last_name>
      <phone>(38169) 109-5002</phone>
      <email>nagornia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aleksandar Nagorni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Djordje Joanovic, Internal Deases Department, Gastroenterology</name>
      <address>
        <city>Zrenjanin</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dusan Slankamenac, MD</last_name>
      <phone>(38169) 226-9372</phone>
      <email>slankamenacdusan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dusan Slankamenac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal medicine</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Juan RamÃ³n Jimenez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Public Enterprise &quot;Dnipropetrovsk regional clinical hospital named after I.I. Mechnikova&quot;, Department of Gastroenterology (Hepatology)</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olha Khodasenko, Dr.</last_name>
      <phone>(38067) 634-8709</phone>
      <email>sipona4@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olha Khodasenko, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MNPE &quot;Regional Clinical Hospital of Ivano-Frankivsk Regional Council&quot;, Gastroenterology Department, SHEI &quot;Ivano-Frankivsk National Medical University&quot;, Chair of Internal Medicine #1</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Yatsyshyn, Dr.</last_name>
      <phone>(38050) 338-8571</phone>
      <email>yatsyshyn25@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roman Yatsyshyn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk City Clinical Hospital No. 1</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergiy Fedorov, Dr.</last_name>
      <email>serfed@i.ua</email>
    </contact>
    <investigator>
      <last_name>Sergiy Fedorov, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital #2 named after prof. O.O. Shalimova&quot;, of Kharkiv City Council, Proctology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Datsenko, Dr.</last_name>
      <phone>(38067) 570-8650</phone>
      <email>edatsenko@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Olena Datsenko, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise of Kharkiv Regional Council &quot;Regional Clinical Hospital&quot;, Gastroenterology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryna Zinchenko, Dr.</last_name>
      <phone>(38050) 402-2938</phone>
      <email>marinazinchenkorch@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Maryna Zinchenko, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Enterprise Private Manufacturing Firm &quot;Acinus&quot;, Treatment and diagnostic Centre</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktorya Shevchuk, Dr.</last_name>
      <phone>(38066) 963-7258</phone>
      <email>shevchukvika1975@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Viktorya Shevchuk, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #18, Proctology Department, National Medical University named after O.O.Bogomolets, Chair of Surgery #1</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #1, Therapeutics Department #2</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inna Markevych, Dr.</last_name>
      <phone>(38067) 402-8636</phone>
      <email>inna.markevich@okclinic.com.ua</email>
    </contact>
    <investigator>
      <last_name>Inna Markevych, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Limited Liability Company &quot;Medical Centre &quot;Dopomoga plus&quot;&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>02132</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yurii Zakharash, Dr. Med.Sci., Prof.</last_name>
      <phone>(38067) 321-6127</phone>
      <email>dopomoga.trial@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yurii Zakharash, Dr. Med.Sci., Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;Consultative and Diagnostic Centre&quot; of Desnianskyi District of Kyiv, Surgery Department</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Shalimov's National Institute of surgery and transplantation</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tetiana Marian, Dr.</last_name>
      <phone>(38050) 331-8393</phone>
      <email>tetiana.marian@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tetiana Marian, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Limited Liability Company &quot;Medical Centre &quot;Consilium Medical&quot;, clinico-consultation department</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oksana Gerasymenko, PhD</last_name>
      <phone>(38097) 913-2763</phone>
      <email>ogconmed@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oksana Gerasymenko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Institution of the Kyiv Regional Council &quot;Kyiv Regional Clinical Hospital&quot;, Gastroenterology Department</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmytro Shulga, Dr.</last_name>
      <phone>(38095) 896-9484</phone>
      <email>nataliyasydor@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Dmytro Shulga, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise of Lviv Regional Council &quot;Lviv Regional Clinical Hospital&quot;, proctology department, Danylo Galytsky Lviv National Medical University, Chair of Surgery #1</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyubov Lozynska, PhD</last_name>
      <phone>(38067) 253-4194</phone>
      <email>lyuba.lozynska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lyubov Lozynska, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Clinical Hospital named after Andriy Novaka, gastroenterology department</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaroslava Rishko, Dr.</last_name>
      <phone>(38099) 727-9631</phone>
      <email>rishko.yaroslava@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yaroslava Rishko, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Vinnytsia Regional Clinical Hospital named after M.I. Pyrogova of Vinnytsia Regional Council, Regional Specialized Clinical Gastroenterological Center,</name>
      <address>
        <city>Vinnytsia</city>
        <zip>20128</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliia Kizlova, Dr.</last_name>
      <phone>(38097) 297-3221</phone>
      <email>gastrovokl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nataliia Kizlova, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Vinnytsia City Clinical Hospital #1, Gastroenterology Department, Vinnytsia National Medical University named after M.I.Pyrogova, Chair of Propaedeutics of Internal Medicine</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halyna Tomashkevych, Dr.</last_name>
      <phone>(38067) 257-5854</phone>
      <email>htomasha@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Halyna Tomashkevych, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Zaporizhzhska Regional Clinical Hospital&quot; of Zaporizhzha Regional Council, gastroenterology department</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Kulynych, Dr.</last_name>
      <phone>(38066) 185-2438</phone>
      <email>Cardiolog1978@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roman Kulynych, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London North West University Healthcare NHS Trust (LNWH), St Mark's Hospital, R&amp;D Department, Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pooja Datt</last_name>
      <phone>(440208) 869-5808</phone>
      <email>pooja.datt@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ailsa Hart, BA (Hons), BMBCh, FRCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust, of Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ceri Guarnieri</last_name>
      <phone>(440208) 539-5522</phone>
      <phone_ext>6730</phone_ext>
      <email>Ceri.Guarnieri@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sami Hoque, MD FRCP PhD(Edin) FACG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Theis</last_name>
      <phone>(440203) 447-7480</phone>
      <email>belinda.theis@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Farooq Rahman, BSc(Hons) PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Helens &amp; Knowsley Teaching Hospitals NHS Trust, Whiston Hospital</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Robinson</last_name>
      <phone>(440151) 676-5828</phone>
      <email>Stephanie.Robinson@sthk.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rajiv Chandy, MBBS,MD,DNB(Gastro),FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust, University Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subiatu Wurie</last_name>
      <phone>(440247) 696-6098</phone>
      <email>Subiatu.Wurie@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ramesh Arasardanam, MB BcH BaO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shrewsbury and Telford Hospitals NHS Trust, Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Wilcox</last_name>
      <phone>(440174) 326-1000</phone>
      <phone_ext>3387</phone_ext>
      <email>Rebecca.Wilcox@sath.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Butterworth, MB BCh, MRCP (UK)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust, New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pardeep Atwal, PhD, FRCP</last_name>
      <phone>(440190) 230-7999</phone>
      <phone_ext>4112</phone_ext>
      <email>p.atwal@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Matthew Brookes, PhD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Netherlands</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211431.pdf</url>
    <description>European Medicines Agency (EMA). Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis.[Online]. 2016.</description>
  </link>
  <link>
    <url>https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM515143.pdf</url>
    <description>US Food and Drug Administration (FDA). Ulcerative Colitis: Clinical Trial Endpoints. Guidance for Industry.[Online]. 2016.</description>
  </link>
  <link>
    <url>http://www.auanet.org/guidelines/asymptomatic-microhematuria</url>
    <description>American Urological Association. Guideline: Diagnosis, evaluation and follow up of asymptomatic mircrohematuria. (AMH) in adults.[Online]. 2012.</description>
  </link>
  <link>
    <url>http://eurlex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31995L0046</url>
    <description>European Union (EU). Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. [Online].</description>
  </link>
  <link>
    <url>http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679</url>
    <description>EU. Regulation 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016; [Online].</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>IMU-838</keyword>
  <keyword>vidofludimus calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

